

Publications de l'IFM

Intergroupe Francophone du Myélome

2013

1. Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchnignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Femand JP, Avet-Loiseau H, Facon T. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. *Blood*. 2013 Jan 14[Epub ahead of print]
2. Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Lorraine Chrétien M, Arnulf B, Szalat R, Garderet L, Benajiba L, Pegourie B, Regny C, Royer B, Caullier A, Stoppa AM, Garciaz S, Touzeau C, Chaletteix C, Femand JP, Avet-Loiseau H, Facon T, Attal M, Moreau P. Consolidation with VTD significantly improves the complete remission rate and time to progression following VTD induction and single autologous stem cell transplantation in multiple myeloma. *Leukemia* 2013 Apr5 [Epub ahead of print]
3. Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, Royer B, Dib M, Voillat L, Bouscary D, Caillot D, Wetterwald M, Pégourie B, Lepeu G, Corront B, Karlin L, Stoppa AM, Fuzibet JG, Delbrel X, Guilhot F, Kolb B, Decaux O, Lamy T, Garderet L, Allangba O, Lifermann F, Anglaret B, Moreau P, Harousseau JL, Facon T. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma : the intergroupe francophone du myelome experience. *J Clin Oncol*. 2013 Aug 1;31(22):2806-9.
4. Hebraud B, Caillot D, Corre J, Marit G, Hulin C, Leleu X, Lode L, Wetterwald M, Dib M, Rodon P, Voillat L, Royer B, Voog E, Fitoussi O, Stoppa AM, Garderet L, Kolb B, Maigre M, Boullanger N, Allangba O, Karlin L, Daguindeau N, Legros L, Sohn C, Joubert MV, Lenain P, Facon T, Attal M, Moreau P, Avet-Loiseau H. The translocation t(4;14) can be present only in minor subclones in multiple myeloma. *Clin Cancer Res*. 2013 Jul 15. [Epub ahead of print]
5. Leleu X, Rodon P, Hulin C, Daley L, Dauriac C, Hacini M, Decaux O, Eisemann JC, Fitoussi O, Lioure B, Voillat L, Slama B, Al Jijakli A, Benramdane R, Chaletteix C, Costello R, Thyss A, Mathiot C, Boyle E, Maloisel F, Stoppa AM, Kolb B, Michallet M, Lamblin A, Natta P, Facon T, Elalamy I, Femand JP, Moreau P. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. *Thromb Haemos*. 2013 Aug 1;110(4). [Epub ahead of print]
6. Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, Karlin L, Hulin C, Gentil C, Guilhot F, Garderet L, Lamy T, Brechnignac S, Pegourie B, Jaubert J, Dib M, Stoppa AM, Sebban C, Fohrer C, Fontan J, Fruchart C, Macro M, Orsini-Piocelle F, Lepeu G, Sohn C, Corre J, Facon T, Moreau P, Attal M, Avet-Loiseau H. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: The IFM experience on 1195 patients. *Leukemia* 2013 Jul 29. doi: 10.1038/leu.2013.225. [Epub ahead of print]
7. Michallet M, Sobh M, El-Cheikh J, Morisset S, Sirvent A, Reman O, Cornillon J, Tabrizi R, Milpied N, Harousseau JL, Labussière H, Nicolini FE, Attal M, Moreau P, Mohty M, Blaise D, Avet-Loiseau H. Tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high-risk multiple myeloma patients : evolving strategies with the immunomodulating drugs. *Exp Hematol* 2013 Aug 29. [Epub ahead of print]

8. Caillon H, Dejoie T, Le Loupp AG, Azoulay-Fauconnier C, Masson D, Moreau P, Denis M, Avet-Loiseau H. Difficulties in immunofixation analysis: a concordance study on the IFM 2007-02 trial. *Blood Cancer J*. 2013 Oct 25;3:e154. doi: 10.1038/bcj.2013.51.

2014

9. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammass MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. *Nat Commun*. 2014 Jan 16;5:2997. doi: 10.1038/ncomms3997.

10. Fouquet G, Hébraud B, Garcia S, Stoppa AM, Roussel M, Caillot D, Chretien ML, Arnulf B, Szalat R, Garderet L, Benajiba L, Pégourie B, Regny C, Royer B, Caulier A, Touzeau C, Tessoulin B, Fermand JP, Facon T, Attal M, Avet-Loiseau H, Moreau P, Leleu X. Partial response at completion of bortezomib-thalidomide-dexamethasone (VTD) induction regimen upfront in multiple myeloma does not preclude response to VTD in consolidation. *J Cancer* 2014 ;11 :248-252.

11. Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L, Roussel M, Stoppa AM, Guilhot F, Lamy T, Garderet L, Pegourie B, Dib M, Sebban C, Lenain P, Brechignac S, Royer B, Wetterwald M, Legros L, Orsini-Piocelle F, Voillat L, Delbrel X, Caillot D, Macro M, Facon T, Attal M, Moreau P, Avet-Loiseau H, Corre J. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. *Haematologica*. 2014 Apr 11. [Epub ahead of print]

12. Amin SB, Yip WK, Minvielle S, Broyl A, Li Y, Hanlon B, Swanson D, Shah PK, Moreau P, van der Holt B, van Duin M, Magrangeas F, Sonneveld P, Anderson KC, Li C, Avet-Loiseau H, Munshi NC. Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. *Leukemia*. 2014 Apr 15. doi: 10.1038/leu.2014.140. [Epub ahead of print]

13. Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi AM, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Bladé J, Petrucci MT, Neben K, San Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JT. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del 17p identifies patients with multiple myeloma treated with frontline autologous stem cell transplantation at high-risk of early MM progression-related death. *J Clin Oncol* 2014 Jun2. [Epub ahead of print]

14. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa AM, Gentil C, Wulleme S, Huynh A, Hebraud B, Corre J, Chretien ML, Facon T, Avet-Loiseau H, Attal M. Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome. *J Clin Oncol*. 2014 Jul 14. pii: JCO.2013.54.8164. [Epub ahead of print]

15. Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, Herbaux C, Noel MP, Manier S, Schraen S, Onraed B, Faucompré JL, Hennache B, Petillon MO, Mathiot C, Avet-Loiseau H, Facon T, Harding SJ, Moreau P, Leleu X. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. *Cancer*. 2014 Aug 12. doi: 10.1002/cncr.28946. [Epub ahead of print]

16. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Galdes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder

D., Anderson K, Ferman J, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med* 2014;371:906-917

17. Moreau P, Hulin C, Facon T. Frontline therapy for patients with multiple myeloma not eligible for stem cell transplantation. *Hematol Oncol Clin N Am* 2014;28:829-838.

18. Moreau P, Mary JY, Attal M. Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. *Br J Haematol* 2014, Published Online 19Sep2014

19. Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. *Bone Marrow Transplant*. 2014 Nov 10. doi: 10.1038/bmt.2014.255. [Epub ahead of print]

20. Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Benboubker L, Jardel H, Decaux O, Kolb B, Roussel M, Garderet L, Leleu X, Fitoussi O, Chateix C, Casassus P, Lenain P, Royer B, Banos A, Benramdane R, Cony-Makhoul P, Dib M, Fontan J, Stoppa AM, Traulle' C, Vilque JP, Pétilion MO, Mathiot C, Dejoie T, Avet-Loiseau H, Moreau P. Phase 2 study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. *Haematologica*. 2014 Nov 14. pii: haematol.2014.110890. [Epub ahead of print]

21. Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Ferman J, Moreau P, Attal M, Avet-Loiseau H, Facon T. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02. *Blood*. 2015 Jan 9. pii: blood-2014-11-612069. [Epub ahead of print]

2015

22. Hebraud B, Magrangeas F, Cleynen A, Lauwers-Cances V, Chretien ML, Hulin C, Leleu X, Yon E, Marit G, Karlin L, Roussel M, Stoppa AM, Belhadj K, Voillat L, Garderet L, Macro M, Caillot D, Mohty M, Facon T, Moreau P, Attal M, Munshi N, Corre J, Minvielle S, Avet-Loiseau H. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. *Blood*. 2015 Jan 30. pii: blood-2014-07-587964. [Epub ahead of print]

23. Moreau P, Attal M. All transplantation-eligible patients with myeloma should receive ASCT in first response. *Hematology Am Soc Hematol Educ Program*. 2014 Dec 5;2014(1):250-254. Epub 2014 Nov 18.

24. Moreau P, Kolb B, Attal M, Caillot D, Benboubker L, Tiab M, Touzeau C, Leleu X, Roussel M, Chateix C, Planche L, Chiffolleau A, Fortin J, Avet-Loiseau H, Mary JY, Hulin C, Facon T. Phase I/II study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. *Blood*. 2015 Mar 17. pii: blood-2015-02-626168. [Epub ahead of print].

25. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. *Blood*. 2015 Apr 2. pii: blood-2014-09-568915. [Epub ahead of print]

26 Richardson PG, Moreau P, Laubach JP, Gupta N., Hui AM, Anderson KC, San Miguel JF, Kumar S, The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. *Future Oncol*. 2015;11(8) 1153-68.

27 Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Groneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, et al ELOQUENT 2 investigators. *N. Engl. J. Med.* 2015 Aug 13;373(7):621-31.

28 Weisel K, Dimopoulos M, Song KW, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Gibson CJ, Zaki M, Jacques C, San Miguel J. *Clin Lymphoma Myeloma Leuk* 2015 Sept; 15(9):519-30.